Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
Harrow has re-launched VERKAZIA, its FDA-approved cyclosporine ophthalmic emulsion, for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. The company is deploying a comprehensive commercial strategy focused on physician education, patient access, and affordability to ensure dependable supply and remove access barriers.
Key figures
- Inadequately controlled on antihistamines
- 61%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.